Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
0(0%)
Results Posted
118%(13 trials)
Terminated
2(15%)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_1
6
46%
Ph phase_2
5
38%
Ph phase_3
1
8%

Phase Distribution

7

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(11)
Terminated(2)

Detailed Status

Completed11
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
84.6%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (7.7%)
Phase 16 (46.2%)
Phase 25 (38.5%)
Phase 31 (7.7%)

Trials by Status

terminated215%
completed1185%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_1

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972
completedphase_1

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

NCT04468347
completedearly_phase_1

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
completedphase_1

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713
completedphase_2

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03052972Phase 1

Flortaucipir 18F PET Imaging in BIOCARD Study

Terminated
NCT04468347Phase 1

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Completed
NCT04474405Early Phase 1

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Completed
NCT03040713Phase 1

Flortaucipir PET Imaging in Subjects With FTD

Completed
NCT02016560Phase 2

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

Completed
NCT02278354Phase 1

Tau Imaging in Professional Fighters

Completed
NCT02278367Phase 2

Clinical Evaluation of Flortaucipir F 18

Completed
NCT01992380Phase 1

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

Completed
NCT02051764Phase 2

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Terminated
NCT02167594Phase 1

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

Completed
NCT03901105Phase 3

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Completed
NCT03322462Phase 2

Tau Screening Study in Patients With Early Symptomatic AD

Completed
NCT03467477Phase 2

Tau Screening Study in Subjects With Early Symptomatic AD

Completed

All 13 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
13